Nakayama, H.; Aisa, Y.; Ito, C.; Sakurai, A.; Nakazato, T.
The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone. Hematol. Rep. 2024, 16, 593-602.
https://doi.org/10.3390/hematolrep16040058
AMA Style
Nakayama H, Aisa Y, Ito C, Sakurai A, Nakazato T.
The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone. Hematology Reports. 2024; 16(4):593-602.
https://doi.org/10.3390/hematolrep16040058
Chicago/Turabian Style
Nakayama, Hitomi, Yoshinobu Aisa, Chisako Ito, Aki Sakurai, and Tomonori Nakazato.
2024. "The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone" Hematology Reports 16, no. 4: 593-602.
https://doi.org/10.3390/hematolrep16040058
APA Style
Nakayama, H., Aisa, Y., Ito, C., Sakurai, A., & Nakazato, T.
(2024). The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone. Hematology Reports, 16(4), 593-602.
https://doi.org/10.3390/hematolrep16040058